PL3687513T3 - Leczenie zespołu łamliwego chromosomu x i autyzmu z użyciem kannabidiolu - Google Patents

Leczenie zespołu łamliwego chromosomu x i autyzmu z użyciem kannabidiolu

Info

Publication number
PL3687513T3
PL3687513T3 PL18788905T PL18788905T PL3687513T3 PL 3687513 T3 PL3687513 T3 PL 3687513T3 PL 18788905 T PL18788905 T PL 18788905T PL 18788905 T PL18788905 T PL 18788905T PL 3687513 T3 PL3687513 T3 PL 3687513T3
Authority
PL
Poland
Prior art keywords
chromosom
cannabidiol
breakable
treatment
autism syndrome
Prior art date
Application number
PL18788905T
Other languages
English (en)
Inventor
Marcel Bonn-Miller
Nancy TICH
Donna Gutterman
John MESSENHEIMER
Terri Sebree
Original Assignee
Zynerba Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zynerba Pharmaceuticals, Inc. filed Critical Zynerba Pharmaceuticals, Inc.
Publication of PL3687513T3 publication Critical patent/PL3687513T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL18788905T 2017-09-28 2018-09-27 Leczenie zespołu łamliwego chromosomu x i autyzmu z użyciem kannabidiolu PL3687513T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762564834P 2017-09-28 2017-09-28
US201862632532P 2018-02-20 2018-02-20
PCT/IB2018/057519 WO2019064234A1 (en) 2017-09-28 2018-09-27 TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
EP18788905.0A EP3687513B1 (en) 2017-09-28 2018-09-27 Treatment of fragile x syndrome and autism with cannabidiol

Publications (1)

Publication Number Publication Date
PL3687513T3 true PL3687513T3 (pl) 2022-04-19

Family

ID=63878731

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18788905T PL3687513T3 (pl) 2017-09-28 2018-09-27 Leczenie zespołu łamliwego chromosomu x i autyzmu z użyciem kannabidiolu

Country Status (22)

Country Link
US (13) US10213390B1 (pl)
EP (3) EP3687513B1 (pl)
JP (5) JP7210564B2 (pl)
KR (2) KR102786277B1 (pl)
AU (2) AU2018343256B2 (pl)
BR (1) BR112020005918A2 (pl)
CA (2) CA3300266A1 (pl)
CY (1) CY1125071T1 (pl)
DK (1) DK3687513T3 (pl)
ES (2) ES2992838T3 (pl)
HR (1) HRP20220277T1 (pl)
HU (1) HUE058102T2 (pl)
IL (1) IL273495A (pl)
JO (1) JOP20200082B1 (pl)
LT (1) LT3687513T (pl)
MX (2) MX2020003606A (pl)
PL (1) PL3687513T3 (pl)
PT (1) PT3687513T (pl)
RS (1) RS62969B1 (pl)
SI (1) SI3687513T1 (pl)
SM (1) SMT202200093T1 (pl)
WO (1) WO2019064234A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12582664B2 (en) 2017-09-28 2026-03-24 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
CA3300266A1 (en) 2017-09-28 2026-03-02 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
IL325123A (en) 2018-12-14 2026-02-01 Harmony Biosciences Man Inc Treating 22q11.2 Deficiency Syndrome with Cannabidiol
GB201912760D0 (en) * 2019-09-05 2019-10-23 Healx Ltd Treatment
WO2021055499A1 (en) * 2019-09-17 2021-03-25 Zynerba Pharmaceuticals, Inc. Treatment of behavioral impairment in developmental and epileptic encephalopathy
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
JP2022551730A (ja) 2019-10-14 2022-12-13 パイク セラピューティクス,インコーポレイテッド カンナビジオールの経皮送達
GB2589306A (en) * 2019-10-25 2021-06-02 Gw Res Ltd Use of cannabidiol preparations in the treatment of fragile X syndrome
WO2021158059A1 (ko) 2020-02-07 2021-08-12 건국대학교 글로컬산학협력단 릴메니딘 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물
JP7856584B2 (ja) * 2020-05-26 2026-05-11 ハーモニー・バイオサイエンシズ・マネージメント・インコーポレイテッド カンナビジオールを用いた自閉症スペクトラム障害の処置
TWI902836B (zh) * 2020-06-29 2025-11-01 美商和諧生物科學管理股份有限公司 以大麻二酚(cannabidiol)治療X染色體脆折症候群
AU2021392090A1 (en) * 2020-12-03 2023-07-06 Harmony Biosciences Management, Inc. Cannabidiol for the treatment of refractory seizures
CN116782891A (zh) * 2020-12-03 2023-09-19 Zyne制药公司 大麻二酚对难治性癫痫发作的治疗
CN118284412A (zh) * 2021-10-22 2024-07-02 Zyne制药公司 伴中度至重度焦虑和/或社交回避的自闭症谱系障碍受试者易怒症的治疗

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
FI111733B (fi) 2002-02-20 2003-09-15 Pedipharm Oy Uudet metyloidut syklodekstriinikompleksit
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20080139472A1 (en) * 2006-10-06 2008-06-12 The Regents Of The University Of California Upregulating bdnf levels to mitigate mental retardation
DK2176208T3 (en) 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
WO2010127033A1 (en) 2009-04-28 2010-11-04 Alltranz Inc. Formulations of cannabidiol and methods of using the same
PT2473475T (pt) 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
AU2014206036B2 (en) 2013-01-08 2017-11-02 Universidade De Sao Paulo - Usp Fluorinated CBD compounds, compositions and uses thereof
US9943491B2 (en) 2013-10-29 2018-04-17 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
US20160022627A2 (en) 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
US20160271252A1 (en) 2014-05-29 2016-09-22 Insys Development Company, Inc. Stable cannabinoid formulations
CA2950424C (en) 2014-05-29 2023-03-14 Insys Pharma, Inc. Stable cannabinoid formulations
US12544389B2 (en) 2014-05-29 2026-02-10 Fresh Cut Development, Llc Stable cannabinoid formulations
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
EP3160451B1 (en) 2014-06-27 2021-04-07 Farm To Farma, Inc. Buccal and sublingual cannabinoid formulations and method of making the same
WO2016004121A1 (en) 2014-07-01 2016-01-07 MJAR Holdings, LLC High cannabidiol cannabis strains
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
MX2017005277A (es) 2014-10-21 2018-01-11 United Cannabis Corp Extractos de cannabis y métodos de preparación y uso de la misma.
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
WO2016109624A1 (en) 2014-12-30 2016-07-07 University Of Houston System Pharmaceutical compositions
BR112017018944A2 (en) 2015-03-02 2018-05-15 Afgin Pharma, Llc method of treating a disease state or condition in humans with a carbinoid drug, and method of treating a disease state or condition in a mammal other than a human with carbinoid drug (s)
US20160338974A1 (en) 2015-03-02 2016-11-24 Afgin Pharma, Llc Topical regional neuro affective therapy with cannabinoid combination products
WO2017068349A1 (en) 2015-10-23 2017-04-27 E-Therapeutics Plc Cannabinoid for use in immunotherapy
WO2017151980A1 (en) 2016-03-03 2017-09-08 Segreti Louis M Cannabis-based bioactive formulations and methods for use thereof
WO2017149387A1 (en) 2016-03-04 2017-09-08 Sharon Anavi-Goffer Compositions of cb2 receptor selective agonists for treatment of mental disorders
PT3429580T (pt) 2016-03-16 2025-08-12 Buzzelet Development And Technologies Ltd Composição de canabinoides enriquecida em terpenos
GB2549277B (en) 2016-04-11 2021-02-17 Gw Res Ltd Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder
GB2549278B (en) 2016-04-11 2021-02-17 Gw Res Ltd Use of cannabidivarin in the treatment of autism spectrum disorder
WO2017182950A1 (en) 2016-04-19 2017-10-26 Canabuzz-Med Cannabis-enriched enzymatically treated therapeutic composition
WO2017208072A2 (en) 2016-06-02 2017-12-07 Acerus Pharmaceutical Corporation Nasal cannabidiol compositions
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
IL246790A0 (en) 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
CN107126411A (zh) * 2017-03-22 2017-09-05 哈尔滨惠美佳生物科技有限公司 具有缓解神经性头痛作用的大麻二酚凝胶及其制备方法
JP2020530857A (ja) 2017-08-14 2020-10-29 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 経皮カンナビジオールゲルを用いた変形性関節症の治療方法
SG11202002169TA (en) 2017-09-15 2020-04-29 Zelda Therapeutics Operations Pty Ltd Composition and method for treating autism
CA3300266A1 (en) 2017-09-28 2026-03-02 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
US12582664B2 (en) 2017-09-28 2026-03-24 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
EP3704263A4 (en) 2017-10-30 2021-08-25 Endocanna Health, Inc. GRAPHIC USER INTERFACES FOR DETERMINING PERSONALIZED ENDOCANNABINOID GENOTYPES AND RELATED RECOMMENDATIONS
WO2019224824A1 (en) 2018-05-24 2019-11-28 To Pharmaceuticals Llc Cannabis-based compositions for the treatment of autistic spectrum disorders
US20230000793A1 (en) 2018-12-14 2023-01-05 Zynerba Pharmaceuticals, Inc. Treatment of 22q11.2 deletion syndrome with cannabidiol
US20230000792A1 (en) 2018-12-14 2023-01-05 Zynerba Pharmaceuticals, Inc. Treatment of 22q11.2 deletion syndrome with cannabidiol
IL325123A (en) 2018-12-14 2026-02-01 Harmony Biosciences Man Inc Treating 22q11.2 Deficiency Syndrome with Cannabidiol
JP7856584B2 (ja) 2020-05-26 2026-05-11 ハーモニー・バイオサイエンシズ・マネージメント・インコーポレイテッド カンナビジオールを用いた自閉症スペクトラム障害の処置
TWI902836B (zh) 2020-06-29 2025-11-01 美商和諧生物科學管理股份有限公司 以大麻二酚(cannabidiol)治療X染色體脆折症候群
GB2597322A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
CN118284412A (zh) 2021-10-22 2024-07-02 Zyne制药公司 伴中度至重度焦虑和/或社交回避的自闭症谱系障碍受试者易怒症的治疗

Also Published As

Publication number Publication date
CA3300266A1 (en) 2026-03-02
US12226373B2 (en) 2025-02-18
EP3967301B1 (en) 2024-06-19
US10758497B2 (en) 2020-09-01
US20250134833A1 (en) 2025-05-01
US20190262280A1 (en) 2019-08-29
US20220096396A1 (en) 2022-03-31
US11458110B2 (en) 2022-10-04
JP2020535190A (ja) 2020-12-03
KR20200058513A (ko) 2020-05-27
BR112020005918A2 (pt) 2020-10-06
AU2018343256A1 (en) 2020-04-02
US12213951B2 (en) 2025-02-04
MX2020003606A (es) 2020-10-28
US10314792B2 (en) 2019-06-11
CY1125071T1 (el) 2023-06-09
US20250134832A1 (en) 2025-05-01
JP2025061375A (ja) 2025-04-10
ES2907325T3 (es) 2022-04-22
JP7210564B2 (ja) 2023-01-23
CA3077330A1 (en) 2019-04-04
HUE058102T2 (hu) 2022-07-28
WO2019064234A1 (en) 2019-04-04
DK3687513T3 (da) 2022-03-07
PT3687513T (pt) 2022-03-01
US20200360299A1 (en) 2020-11-19
JP2022064988A (ja) 2022-04-26
US20190167605A1 (en) 2019-06-06
ES2992838T3 (en) 2024-12-18
US10471022B2 (en) 2019-11-12
EP3967301A1 (en) 2022-03-16
US20230364028A1 (en) 2023-11-16
US20200214995A1 (en) 2020-07-09
EP4414030A3 (en) 2024-11-20
IL273495A (en) 2020-05-31
KR102786277B1 (ko) 2025-03-26
KR20220045070A (ko) 2022-04-12
US20200030255A1 (en) 2020-01-30
US20230000790A1 (en) 2023-01-05
RS62969B1 (sr) 2022-03-31
JP2025106310A (ja) 2025-07-15
US10568848B2 (en) 2020-02-25
US20190117588A1 (en) 2019-04-25
MX2022012424A (es) 2022-11-30
EP3687513A1 (en) 2020-08-05
US20230414533A1 (en) 2023-12-28
AU2024220039A1 (en) 2024-10-17
HRP20220277T1 (hr) 2022-05-13
SI3687513T1 (sl) 2022-04-29
AU2018343256B2 (en) 2024-09-19
JOP20200082A1 (ar) 2020-04-30
SMT202200093T1 (it) 2022-05-12
EP4414030A2 (en) 2024-08-14
EP3687513B1 (en) 2021-12-15
US10213390B1 (en) 2019-02-26
LT3687513T (lt) 2022-03-10
JP2023040166A (ja) 2023-03-22
US11779549B2 (en) 2023-10-10
JOP20200082B1 (ar) 2024-12-22

Similar Documents

Publication Publication Date Title
HUE058102T2 (hu) Fragilis X szindróma és autizmus kezelése kannabidiollal
IL293377B1 (en) Hsd17b13 variants and uses thereof
PL3673080T3 (pl) Oligomery antysensowne do leczenia stanów i chorób
DK3641819T3 (da) Anvendelse af cannabidiol i behandling af tuberøst sklerosekompleks
IL256673B (en) Vascularized in vitro perfusion devices, methods of fabricating, and applications thereof
SI3785717T1 (sl) Postopki za zdravljenje okužb s Coronaviridae
FIC20260013I1 (fi) ikodekinsuliini ja semaglutidi
HUE056612T2 (hu) Hasnyálmirigyrák kezelésének eljárásai paclitaxel és gemcitabin segítségével
HUE037347T2 (hu) Policiklusos karmaboilpiridon vegyületek és alkalmazásuk HIV fertõzések kezelésére
HUE039997T2 (hu) Szulfamoilpirrolamid származékok és alkalmazásuk hepatitisz B kezelésére szolgáló gyógyszerekként
HUE040446T2 (hu) Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére
EP3681479A4 (en) METHOD OF ADMINISTRATION AND TREATMENT
PL3044104T3 (pl) Ampułka do cieczy medycznej i sposób wytwarzania ampułki
PL3370540T3 (pl) Układ adsorpcji i sposób obsługi układu adsorpcji
PL3362084T3 (pl) Urządzenia do podawania dojelitowego i powiązane sposoby zastosowania
PL4335517T3 (pl) Podawanie i dawkowanie diaminofenotiazyn
FI20136131A7 (fi) Suoja, kaareva elementti ja suojan käyttö
EP3334429C0 (en) HYPERPHENYLALANINEMIA AND TREATMENTS THEREFOR
CL2016000392A1 (es) Análogos de cortistatina para el tratamiento de enfermedades con componente inflamatorio y/o inmune
HUE054185T2 (hu) Eozinofilek és/vagy bazofilek megemelkedett szintjének kezelése
IL258997B (en) Honey-cannabinoid therapeutic composition
EP3546007A4 (en) CATHETER AND BALLOON CATHETER
EP3517161A4 (en) CATHETER AND BALLOON CATHETER
EP3558293C0 (en) SMALL MOLECULES INHIBITING SOX18 PROTEIN ACTIVITY IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOGENESIS AND/OR LYMPHANGIOGENESIS
EP3601223A4 (en) ISOTOPE-ENRICHED 3-AMINO-1-PROPANESULPHONIC ACID DERIVATIVES AND THEIR USES